Phase 1 / 2 Study of Elranatamab in People with Relapsed/Refractory Multiple Myeloma MAGNETISMM-9

What's the purpose of this trial?

The goal of this clinical trial is to evaluate the safety and effectiveness of different doses and dose intervals of Elranatamab in people with relapsed/refractory multiple myeloma.

This trial is currently open and accepting patients.

What will happen during the trial?

This Phase 1 / 2 clinical trial is being conducted in two different parts. It is open-label, which means that both patient and researchers will know which group they are participating in and which doses they will receive. Patients enrolling in this trial will be allowed to continue to receive Elranatamab as long as their myeloma doesn’t get worse, and they don’t develop bad side effects.

Part 1
Part 1 of this study is organized into 28 day cycles. Researchers are seeking approximately 30 participants in this part of the study. All participants will be required to be hospitalized for a minimum of three days while receiving their first doses of Elranatamab in cycle 1. Patients participating in Part 1 of this study will receive Elranatamab weekly during their first 6 cycles, and every other week from cycle 7 onward if they respond well to Elranatamab. 

Part 2 
Part 2 is the dose exploration and expansion part of this trial, and also organized into 28 day cycles. Researchers are seeking approximately 46 participants in Part 2, in up to three different groups. All participants will be required to be hospitalized for a minimum of three days while receiving their first doses of Elranatamab in cycle 1. Some patients in part 2 will also be required to be hospitalized for one day while receiving the first dose in cycle 2. 

Patients in part 2 will receive one of two planned dose levels of Elranatamab weekly or every other week depending on when they join the study. After 4 and 7 cycles, some patients' dosing schedules may change to receive Elranatamab every other week and once a month respectively if they respond well to Elranatamab.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • Have measurable disease as described in the trial protocol.
  • Are refractory to at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD38 antibody.
  • Are relapsed or refractory after your last treatment regimen.
  • Have not had a stem cell transplant in the 12 weeks before enrollment.
  • Have not had previous treatment with an anti-BCMA bispecific antibody.

Additional Trial Information

Phase 2

Enrollment: 76 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Mayo Clinic (Arizona)

Phoenix, AZ

Open and Accepting


University of Colorado Health - Poudre Valley Hospital Poudre Valley Hospital

Fort Collins, CO

Open and Accepting


Shands Hospital University of Florida Health

Gainesville, FL

Open and Accepting


Pikeville Medical Center

Pikeville, KY

Open and Accepting


Tulane Cancer Center Tulane University School of Medicine

New Orleans, LA

Open and Accepting


Tufts Medical Center Cancer Center

Boston, MA

Open and Accepting


University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Open and Accepting

Henry Ford Hospital

Detroit, MI

Open and Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Open and Accepting


Cleveland Clinic Taussig Cancer Institute

Cleveland, OH

Open and Accepting


Fox Chase Cancer Center Temple Health

Philadelphia, PA

Open and Accepting


St. David's South Austin Medical Center

Austin, TX

Open and Accepting

Methodist Hospital

San Antonio, TX

Open and Accepting


Huntsman Cancer Institute University of Utah

Salt Lake City, UT

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors